Boston Scientific Corporation

Boston Scientific Corporation

BSXNYSE / NASDAQHealthcareLarge cap

$41.98-$1.01 (-2.3%)

Last close · Data as of Nov 20, 2026

Market cap
$72.6B
P/E
25.1x
EV / EBITDA
16.1x
Revenue
$20.1B
Net margin
14.4%
ROCE
10.4%

-56.5% over the last year

Boston Scientific Corporation price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-7.9%
3M
-15.0%
6M
-25.9%
1Y
-56.5%
5Y
+2.3%

52-week range

Day change -$1.01 (-2.3%) from $43 to $42 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in BSX, bought on each weekday since 2021.

News & filings

What Boston Scientific filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthNet profit grew 60.7% a year over three years.

Concerns (1)

  • The P/E of 25.1 is 44% above the peer median of 17.4.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular.

Read moreShow less

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Sector
Healthcare
Shares outstanding
1.48B

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$72.6B
P/E
25.1x
P/B
3.0x
EV / EBITDA
16.1x
EV / Sales
4.1x
P/S
3.6x
52-week high
$101.58
52-week low
$41.58

Profitability

Operating margin
19.8%
Net margin
14.4%
EBITDA margin
25.4%
ROE
12.0%
ROCE
10.4%
ROA
6.6%
Asset turnover
0.46

Growth

Revenue
$20.1B
Revenue growth, 1Y
19.9%
Revenue CAGR, 3Y
16.5%
Net profit growth, 1Y
56.3%
Free cash flow
$3.4B

Solvency

Current ratio
1.62
Debt / Equity
0.47
Debt / Assets
0.26
CFO / Net profit
1.56
Cash / Market cap
2.7%

Where the revenue went

Of every $100 of FY2025 revenue, $14 was left as net income.

Boston Scientific Corporation income statement flow, FY2025
Boston Scientific Corporation income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$6.2B
RevenueGross profit$13.9B
Gross profitResearch and development$2.1B
Gross profitSelling, general and administrative$6.9B
Gross profitOther operating expenses$943.0M
Gross profitOperating income$4.0B
Operating incomePretax income$3.4B
Operating incomeInterest and other expense$586.0M
Pretax incomeTax and other$487.0M
Pretax incomeNet income$2.9B

Revenue and net profit

Revenue grew 19.9% in FY2025; net profit is the dashed line.

Boston Scientific Corporation revenue and net profit by fiscal year
Boston Scientific Corporation revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$12.7B$698.0M
FY2023$14.2B$1.6B
FY2024$16.7B$1.9B
FY2025$20.1B$2.9B

Cash flows

FY2025: $4.5B from operations, $3.4B free after investment (dashed).

Boston Scientific Corporation operating and free cash flow by fiscal year
Boston Scientific Corporation operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$1.5B$914.0M
FY2023$2.5B$1.7B
FY2024$3.4B$2.4B
FY2025$4.5B$3.4B

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$20.1B+19.9%1Y
EBITDA
$5.1B+32.3%1Y
Net profit
$2.9B+56.3%1Y
Cash from operations
$4.5B+32.0%1Y
Free cash flow
$3.4B+43.9%1Y
Revenue CAGR, 3Y
16.5%
Net profit CAGR, 3Y
60.7%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$20.1B$5.1B$2.9B$3.4B12.0%+19.9%+56.3%

Monthly returns

Month-by-month returns of BSX across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$43.7B
Liabilities$19.2B
Equity$24.5B
Paid-in capital$21.5B
Retained earnings$5.6B
Treasury stock$2.3B
Minority interest$239.0M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; BSX highlighted.

P/E against peers

BSX trades at 25.1x earnings against a peer median of 17.4x (a 44% premium).

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Boston Scientific CorporationBSXthis companyP/E ↑ premium$72.6B25.1x3.0x12.0%16.1x
McKesson CorporationMCK$91.0B19.1x-41.9x-219.2%13.3x
Elevance Health, Inc.ELV$88.9B15.7x2.0x12.9%—
HCA Healthcare, Inc.HCA$80.3B11.8x-13.3x-112.6%8.2x
The Cigna GroupCI$74.2B12.5x1.8x14.3%10.2x
Regeneron Pharmaceuticals, Inc.REGN$65.9B14.6x2.1x14.4%11.3x
Cencora, Inc.COR$52.6B33.8x34.9x103.1%14.9x
Edwards Lifesciences CorporationEW$50.4B46.9x4.9x10.4%33.2x
Cardinal Health, Inc.CAH$47.2B30.3x-17.0x-56.1%16.7x
Peer median—17.4x1.9x11.6%13.3x

Year-to-date ROI

BSX since 1 January, against earlier years.

Historical volatility

BSX's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Boston Scientific Corporation operating margin by fiscal year
Boston Scientific Corporation operating margin by fiscal year
DateOperating margin
FY202216.0%
FY202317.0%
FY202417.9%
FY202519.8%
LineFY2025
Cost of revenueCost Of Revenue$6.2B
Gross profitGross Profit$13.9B
Operating expensesOperating Expense$9.9B
Research and developmentResearch And Development$2.1B
Selling, general and administrativeSelling General And Administration$6.9B
Other operating expensesOther Operating Expenses$46.0M
Depreciation and amortisationDepreciation And Amortization In Income Statement$897.0M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$897.0M
Amortization$897.0M
Amortisation of intangiblesAmortization Of Intangibles Income Statement$897.0M
Total expensesTotal Expenses$16.1B
Pretax incomePretax Income$3.4B

Learn while you research

Academy chapters picked for Boston Scientific Corporation and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  3. 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  4. 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →